Conflicting results have been reported regarding the association between early cytomegalovirus (CMV) reactivation and relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This prompted us to evaluate the impact of CMV reactivation on outcomes of 155 consecutive adult patients transplanted in our institution. In our study, CMV reactivation did not affect cumulative incidence (CI) of relapse in patients with lymphoproliferative disorders. However, the CI of relapse in patients with myeloproliferative disorders (AML and MPN) was 37% (95% CI, 21-53) in patients without CMV reactivation as opposed to 17% (95% CI, 9-28) in patients with CMV reactivation (p = 0.03). An important correlation between CMV reactivation and relapse was found in patients with MPN; the CI of relapse was 50% (95% CI, 12-80) in patients without CMV reactivation as opposed to only 7% (95% CI, 0-27) in patients with CMV reactivation (p = 0.02). A substantial reduction of relapse in myeloproliferative disorders associated with CMV reactivation was confirmed by multivariate analysis (HR 2.73; 95% CI, 1.09-6.82, p = 0.03) using time-dependent covariates for high-risk disease, older age, RIC conditioning, ATG, grade II-IV acute, and chronic GVHD. To our knowledge, we are the first to show an association of CMV reactivation with relapse reduction in MPN patients. This putative virus vs myeloproliferation effect warrants further research.
Introduction
Cytomegalovirus (CMV) infection is a major infectious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). CMV can reactivate in up to 80% of patients within the first 100 days after transplantation and lead to a multiorgan CMV disease. Despite the advances in the treatment with ganciclovir and foscarnet, CMV disease is still associated with high mortality rates [1] [2] [3] . However, with current strategies of early detection and pre-emptive treatment of CMV infection, the incidence of CMV disease has decreased to <10% [4] [5] [6] . Nevertheless, CMV reactivation is still regarded as harmful because it often results in an increased risk of acute graft-vs-host disease (GVHD) [4, 5] . Moreover, pre-emptive antiviral treatment is associated with drug-induced myelosuppression and consequently more infectious complications [4] [5] [6] . Owing to these indirect adverse effects, CMV infection stays a significant factor associated with an increased non-relapse mortality (NRM) after allo-HSCT.
These concerns have been challenged with studies which suggested that early CMV reactivation d ecreases the risk of disease relapse after allo-HSCT [7] [8] [9] [10] [11] [12] . According to more recent studies, it seems that this protective effect is restricted to patients with acute myeloid leukemia (AML) [13, 14] . On the contrary, the same effect has not been confirmed in patients with acute lymphoblastic leukemia (ALL) [15] , lymphoma [16] , or myelodysplastic syndrome (MDS) [17] . The protective effect of CMV infection has not been confirmed in pediatric leukemias either [18] . The impact of CMV reactivation on the overall survival (OS) has also been controversial due to its known negative effect on NRM. Finally, some evidence suggests that the protective effect of CMV is related to the conditioning regimen and restricted only to patients who receive myeloablative chemotherapy (MAC) before allo-HSCT [19] .
Because of these conflicting results, we wanted to evaluate the impact of early CMV reactivation on disease relapse in our study population. We analyzed outcomes of 155 adult patients who consecutively underwent allo-HSCT at our institution and were followed up for at least 2 years.
Materials and methods

Study design
We conducted a single-center retrospective study of consecutive patients who underwent allo-HSCT and had available follow-up of at least 2 years after the transplant. The study included 155 adult patients transplanted for a hematologic malignancy in University Hospital Centre Zagreb, Croatia between 2011 and 2014. Patients who received cord blood or haploidentical transplant were excluded.
CMV monitoring and pre-emptive treatment
In the first 100 days after allo-HSCT, patients were monitored for CMV reactivation once weekly. The monitoring was done from blood plasma with a real-time quantitative polymerase chain reaction (qPCR). We used COBAS® AmpliPrep/COBAS® TaqMan® CMV Test (CAP/CTM CMV; Roche Diagnostics GmbH, Mannheim, Germany). The lower limit of detection was 150 genome copies/ml of sample. In patients who received antithymocyte globulin (ATG) in the conditioning regimen, any positive result was considered significant for the start of treatment. If patient did not previously receive ATG, treatment was started at the level of CMV viremia ≥500 copies/ml. Patients were treated with intravenous ganciclovir or peroral valganciclovir until two consecutive negative qPCR assay were confirmed.
Definitions and endpoints
Acute and chronic GVHD were diagnosed and graded according to established criteria [20, 21] . Conditioning regimens were classified as myeloablative (MAC) if total body irradiation of 12 Gy, intravenous busulfan 12.8 mg/kg, or cyclophosphamide 120 mg/kg were included in the conditioning regimens; in contrast, regimens were classified as reduced-intensity conditioning (RIC) based on the report by the Center for International Blood and Marrow Transplant Research [22] . Patients were stratified according to age into older (age ≥50 years) and younger group of patients (<50 years). AML and ALL in the first remission, chronic myeloid leukemia (CML) in the first or second chronic phase, and MDS with refractory anemia with or without ringed sideroblasts were defined as standard-risk diseases, and other malignant diseases were defined as high-risk diseases. The primary endpoint was the cumulative incidence (CI) of disease relapse stratified by CMV reactivation. Secondary endpoints included OS and NRM.
Statistical methods
Differences in the proportions and medians of clinical characteristics between the two study groups were compared using chi-square, Fisher exact, or Mann-Whitney tests as appropriate. OS was defined as the time from the day of allo-HSCT to the day of last follow-up. The probability of OS was estimated using the Kaplan-Meier method. Univariate analysis of OS was performed using log-rank test. CI of relapse and NRM were estimated using the CI method treating death as a competitive risk [23] . Groups were compared using Gray's test [24] . The multivariate analysis was performed using the semiparametric proportional hazards model of Fine and Gray [25] and included all significant variables from the univariate analysis as well as previously known risk factors for relapse. A p-value <0.05 was considered to indicate statistical significance.
Results
Patients' and transplantation characteristics and CMV reactivation
The characteristics of patients and transplant are depicted in Table 1 . Between 2011 and 2014, 94 male and 61 female patients underwent allo-HSCT at a median age of 46 years (range 18-64). Among them, most patients (68%) were treated for myeloid malignancies; 71 AML, 11 MDS and 23 myeloproliferative neoplasms (MPN): 10 CML, 11 primary myelofibrosis (PMF), and 2 chronic myelomonocytic leukemia. Thirty-one percent of patients had lymphoproliferative disorders, including 23 ALL, 9 non-Hodgkin lymphoma, 6 multiple myeloma, 5 Hodgkin's disease and 6 chronic lymphocytic leukemia. One patient had aplastic anemia. Sixty-one percent of patients were considered to have a standard-risk disease. The donors were unrelated in 79 cases and related in 76 patients. Most of the patients (72%) received peripheral blood stem cells after a RIC regimen (54%). In 67% of patients, ATG was given as a part of a conditioning regimen for GVHD prophylaxis. Twelve percent of patients had a CMV seronegative status before transplantation. With a median follow-up of 24 months, early CMV reactivation occurred in 95 patients (61%) at a median of 27 days after transplantation. The groups with and without CMV reactivation were comparable (Table 1) , except for acute GVHD. Namely, the group with CMV reactivation had significantly more grade II-IV acute GVHD (55%) when compared to group without CMV reactivation (30%) (p = 0.02). Finally, the CI of chronic GVHD for all patients was 26% (95% CI 19-33) at 24 months, without significant differences between two populations (data not shown).
CMV reactivation and allo-HSCT outcomes
OS in the study population was 51% at 32 months (95% CI, 44-60), while the CI of relapse was 24% (18-31%) at 32 months. There was no significant difference between the relapse incidence between groups with and without CMV reactivation in the whole study population (data not shown). On the contrary, the CI of relapse in patients with myeloproliferative disorders (AML and MPN) was 37% (95% CI, 21-53) in patients without CMV reactivation as opposed to 17% (95% CI, 9-28) in patients with CMV reactivation (p = 0.03) (Fig. 1) . However, CMV reactivation did not significantly affect OS in AML and MPN patients. (62%; 95% CI, 51-76 in patients with CMV reactivation vs 48%, 95% CI, 35-68 in patients without CMV reactivation, p = 0.19) (Fig. 1) . The CI of NRM was also comparable in both groups (17%, 95% CI 7-31 in the group without CMV reactivation as opposed to 24%, 95% CI 14-36 in the group with CMV reactivation, p = 0.52). Also, there were no deaths attributed to CMV reactivation. In lymphoproliferative disorders and MDS, CMV reactivation did not have an effect on the CI of relapse (data not shown). Furthermore, a striking correlation between CMV reactivation and relapse was found in patients with MPN; the CI of relapse was 50% (95% CI, 12-80) in patients without CMV reactivation as opposed to only 7% (95% CI, 0-27) in patients with CMV reactivation (p = 0.02) (Fig. 2) . When compared according to the conditioning regimen, CMV reactivation affected the relapse incidence only in patients with AML and MPN who received MAC conditioning regimen (p = 0.01) (Fig. 3) while it did not have a significant impact in patients who received a RIC regimen (p = 0.61) (Fig. 3) . Finally, CMV reactivation strongly affected the group of AML patients who did not receive ATG in the conditioning regimen; in this group, patients who had CMV reactivation experienced no relapse (0%) compared to 45% (95% CI,15-72) in patients without CMV reactivation (p = 0.01). At the same time, in AML patients who did receive ATG there was no difference in the CI of relapse according to CMV reactivation.
Multivariate analysis
An independent reduction of the relapse risk in myeloproliferative disorders (AML and MPN) was analyzed using time-dependent covariate functions for risk of the disease, age of the recipient, RIC conditioning, use of ATG, grade II-IV acute GVHD, and chronic GVHD ( Table 2 ). In the multivariate analysis, the absence of CMV reactivation stayed a significant risk factor for disease relapse in patients with AML and MPN (hazard ratio 2.73; 95% CI, 1.09-6.82, p = 0.03) together with older age of the recipient (hazard ratio 3.06; 95% CI, 1.26-7.41, p = 0.01) and the absence of chronic GVHD (hazard ratio 3.51; 95% CI, 1.09-11.21, p = 0.03).
Discussion
In summary, our report supports the role of early CMV reactivation in reducing relapse after allo-HSCT in patients with myeloproliferative hematologic malignancies. Overall, our results are in concordance with most previous singlecenter studies. Elmaagacli et al. [13] demonstrated that CMV viremia is a strong and independent predictor of reduced relapse risk and increased survival in adult AML patients after a HLA-identical, MAC allo-HSCT. Manjappa et al. [19] further showed that this protective effect of CMV reactivation on relapse in adult AML patients is influenced by the intensity of the conditioning regimen and related to MAC regimen. Finally, Bao et al. [26] confirmed this strong CMV anti-leukemic effect but in AML patients who received a HLA-identical allo-HSCT after a MAC regimen without ATG. We analyzed a more heterogeneous population and most of our patients received a transplant from an unrelated donor (51%) after an ATG (64%) containing and/ or RIC conditioning regimen (54%). However, in our study, the protective CMV effect also seemed to be more pronounced in patients with myeloproliferative malignancies who received myeloablative conditioning and regimens without ATG. However, in the multivariate analysis, early CMV reactivation reduced the risk of relapse in these patients independently from conditioning regimen or the use of ATG.
On the contrary, in a very large CIBMTR registry analysis, early CMV reactivation did not prevent relapse after transplantation in patients with AML, CML, MDS, or ALL [27] . However, methods of testing, level of viral load as measured by qPCR, and type of treatment received for CMV infection are not reported to the CIBMTR. For this reason, it is possible that the definition of CMV reactivation varied significantly among transplant centers included in this study. Our study is limited by a significantly lower number of patients, but on the other hand, we report a consecutive series of patients, all monitored and treated in a homogeneous manner.
We, as the others [15, 16] , did not confirm the protective effect of CMV infection in lymphoproliferative disorders. However, we found an important reduction of relapse in patients with MPN associated with early CMV reactivation. Our finding is based on a small number of MPN patients, but, to our knowledge, we are the first to report such a striking CMV effect on relapse incidence in this group of patients. MPN patients in our study population were mostly CML and PMF patients, and in most previous studies CMV reactivation in these patients was not associated with protection from relapse [15, 28] . Only Ito et al. [29] reported a beneficial effect of CMV reactivation from relapse in patients with CML. However, in this cohort, the majority of the patients received ex vivo T-cell-depleted grafts, and the relapse incidence was relatively high (49%) compared with other studies (10-15%) [13] [14] [15] 18 ]. As we did not perform ex vivo T-cell depletion of the transplants, the overall relapse incidence in our population was considerably lower (24%). Nevertheless, in our MPN patients who did not develop CMV infection, the CI of relapse was as much as 50% as compared to 7% in MPN patients who reactivated CMV (p = 0.02).
The underlying biological mechanism of CMVassociated relapse reduction remains unknown. Malignant myeloid cells may serve as a reservoir for CMV, and virus reactivation may increase leukemic immunogenicity, making them better targets for leukemia (or viral)-specific T or natural killer (NK) cells [30, 31] . Another possibility is that CMV reactivation enhances graft-vs-leukemia (GVL) effect by direct activation of T or NK cell immune response [32] . Accordingly, the absence of this effect in RIC allo-HSCT, where most patients undergo in vivo T-cell depletion with ATG, underscores the role of donor-derived T cells. Furthermore, it is known that the use of ATG greatly delays the reconstitution of CD4+ T cells. This finding supports the absence of protective CMV effect in patients who receive ATG in the conditioning regimen as well as it underlines the role of immune reconstitution for CMV-induced reduction of relapse. Also, recent reports showed that posttransplantation CMV reactivation initiates long-lasting expansion of NKG2C þ cells, which induce a potent antileukemia response by producing interferon-gamma [33] . In general, the NK cell-mediated GVL effect is more prominent in myeloid than in lymphoid malignancies [34, 35] . This could be the reason why a CMV-associated decreased incidence of relapse was so far observed mainly in patients with AML. Alternatively, dynamic changes of cytokines in the bone marrow milieu after CMV reactivation may boost anti-leukemia immunity through a bystander effect [28] . It is less likely that this anti-leukemic effect occurs due to ganciclovir-mediated myelosuppression.
In most of the previous studies, the reduction of relapse associated with CMV reactivation did not translate into an OS benefit. On the contrary, several studies reported decreased OS in patients with CMV reactivation [36, 37] . This is partly due to more acute GVHD observed in patients with CMV infection, as well as more infections due to viral therapy-related myelosuppression, which together contribute to higher NRM in patients who reactivate CMV. [15, 19, 28] . We also observed significantly more grade II-IV acute GVHD in patients who developed CMV reactivation (55% vs 30%, p = 0.02). However, in our study, this did not result in significantly higher CI of NRM. Moreover, in our study, OS was better in patients with CMV reactivation as compared to patients without (62% vs 48%, respectively) even though this difference did not reach statistical significance.
In conclusion, our findings support the protective effect of early posttransplant CMV reactivation from relapse in patients with myeloproliferative malignancies. Reactivation of CMV was traditionally considered as an adverse event needing prompt and aggressive treatment. New insights such as ours might help in changing this old paradigm and establish new ones that highlight beneficial anti-leukemia effects associated with viral reactivation. However, larger prospective studies are needed and the mechanism responsible for this protective effect of CMV needs to be elucidated. The potential anti-CML and anti-PMF effects associated with CMV reactivation also warrant further research. Ultimately, new findings could lead to the substantial change of current transplant practices including donor selection strategies and pre-emptive targeting of posttransplantation CMV infection in selected hematologic malignancies.
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